Active — Not RecruitingNot Applicable

An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients

China202 participantsStarted 2024-11-14

Plain-language summary

This study is a multicenter, observational, prospective study to evaluate the asthma biologic use features and clinical outcomes in China. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Chinese, Female or Male
✓. Age: no limitation
✓. Physician-confirmed asthma diagnosis with documented evidence of diagnosis or evidence of variable expiratory airflow limitation (e.g., from bronchodilator reversibility testing or other tests).
✓. Participants or their legal guardians must be able to provide informed consent.
✓. Prescription of asthma biologics at enrolment.

Exclusion criteria

✕. Participation in an interventional study within the last 3 months.
✕. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study with the usage of biologics, or may influence the results of the study, or the patient's ability to participate in the study

What they're measuring

the proportion of days covered (PDC) with asthma biologics during 52 weeks

Timeframe: week52

Trial details

NCT IDNCT06605885

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-09-30

View on ClinicalTrials.gov More Asthma trials